Soligenix, Inc. Common Stock (SNGX) — 分析摘要
Soligenix, Inc. Common Stock（SNGX）的市值为5.23百万美元，最近一年的营收同比增长了+0.0%。净利润率为-9282.3%。当前市盈率为-0.5倍。
核心要点
- 营收同比变化+0.0%
- 净利润率-9282.3%
- 市盈率-0.5倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，SNGX的营收增长为+0.0%，市盈率为-0.5倍。
Soligenix, Inc. Common Stock (SNGX)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营收较上一期下降 100.0%。
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
行业
PHARMACEUTICAL PREPARATIONS
员工人数
14
总部
PRINCETON, NJ
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。